Document ID: chunk:federal_register_of_legislation:F2025C00158:clause:4_1:p76
Version: federal_register_of_legislation:F2025C00158
Segment Type: clause
Provision Reference: sch 4 cl 1 (pt 76/191)
Character Range: 10368326–10378996

AND
                                                                                                                                                                                                                               Patient must have had a prior episode of chemotherapy induced nausea or vomiting; AND
                                                                                                                                                                                                                               Patient must be scheduled to be administered a chemotherapy regimen that includes any 1 of the following intravenous chemotherapy agents:
                                                                                                                                                                                                                                arsenic trioxide; azacitidine; cyclophosphamide at a dose of less than 1500 mg per square metre per day; cytarabine at a dose of greater than 1 g per square metre per day; dactinomycin; daunorubicin; doxorubicin; epirubicin; fotemustine; idarubicin; ifosfamide; irinotecan; melphalan; methotrexate at a dose of 250 mg to 1 g per square metre; raltitrexed.
                                                                                                                                                                                                                               No more than 1 vial of fosaprepitant 150 mg injection will be authorised per cycle of cytotoxic chemotherapy.
                                                                                                                                                                                                                               Concomitant use of a 5HT3 antagonist should not occur with fosaprepitant on days 2 and 3 of any chemotherapy cycle.
C6890               P6890          CN6890           Protein formula with carbohydrate, fat, vitamins and minerals                                                                                                              Dietary management of conditions requiring a source of medium chain triglycerides
                                                                                                                                                                                                                               Patient must have fat malabsorption due to liver disease; or
                                                                                                                                                                                                                               Patient must have fat malabsorption due to short gut syndrome; or
                                                                                                                                                                                                                               Patient must have fat malabsorption due to cystic fibrosis; or
                                                                                                                                                                                                                               Patient must have fat malabsorption due to gastrointestinal disorders;
                                                                                                                                                                                                                               Patient must be aged from 1 to 10 years inclusive.
C6891               P6891          CN6891           Fosaprepitant                                                                                                                                                              Nausea and vomiting                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Compliance with Authority Required procedures - Streamlined Authority Code 6891
                                                                                                                                                                                                                               The condition must be associated with cytotoxic chemotherapy being used to treat breast cancer; AND
                                                                                                                                                                                                                               The treatment must be in combination with a 5-hydroxytryptamine receptor (5HT3) antagonist and dexamethasone; AND
                                                                                                                                                                                                                               Patient must be scheduled to be co-administered cyclophosphamide and an anthracycline.
                                                                                                                                                                                                                               No more than 1 vial of fosaprepitant 150 mg injection will be authorised per cycle of cytotoxic chemotherapy.
C6898               P6898          CN6898           Risperidone                                                                                                                                                                Severe behavioural disturbances                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Compliance with Authority Required procedures - Streamlined Authority Code 6898
                                                                                                                                                                                                                               Patient must have autism spectrum disorder; AND
                                                                                                                                                                                                                               The treatment must be under the supervision of a paediatrician or psychiatrist; AND
                                                                                                                                                                                                                               The treatment must be in combination with non-pharmacological measures;
                                                                                                                                                                                                                               Patient must be under 18 years of age.
                                                                                                                                                                                                                               Behaviour disturbances are defined as severe aggression and injuries to self or others where non-pharmacological methods alone have been unsuccessful.
                                                                                                                                                                                                                               The diagnosis of autism spectrum disorder must be made based on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) or ICD-10 international classification of mental and behavioural disorders.
C6910               P6910          CN6910           Testosterone                                                                                                                                                               Androgen deficiency                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Compliance with Authority Required procedures
                                                                                                                                                                                                                               Patient must have an established pituitary or testicular disorder; AND
                                                                                                                                                                                                                               Must be treated by a specialist general paediatrician, specialist paediatric endocrinologist, specialist urologist, specialist endocrinologist or a Fellow of the Australasian Chapter of Sexual Health Medicine; or in consultation with one of these specialists; or have an appointment to be assessed by one of these specialists.
                                                                                                                                                                                                                               The name of